Tuesday, November 28, 2006 8:00:00 AM PDT | VentureDeal Staff
TARRYTOWN, NY -- Cara Therapeutics announced the closing of a Series C round of financing, in the amount of $19 million.The company has developed and licensed a peripherally-acting pain drug, CR665, which is still in clinical trials. Cara has other pain drugs in various stages of trial. The company intends to use the funding to advance two other pain drugs through clinical trials and for working capital through 2008.Investors in the round included MVM Life Science Partners, Alta Biopharma Partners and Ascent Medical Ventures.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
